CClinicalTrials.gg
Not yet recruitingNCT07836764V1BEUpdated Sep 23, 2026

Validation of 1 Minute Sit-to Stand Test for Assessment of Breathlessness at Exertion in Individuals With Chronic Lung Disease

An observational study in COPD (Chronic Obstructive Pulmonary Disease), Asthma (Diagnosis) and Interstitial Lung Disease (ILD), sponsored by Jacob Sandberg. Not yet recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Jacob Sandberg · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Study summary

Breathlessness is a common symptom in people with chronic lung and heart diseases. It can affect daily activities, quality of life, and overall health. Current questionnaires used to assess breathlessness depend on a person's memory of symptoms and may not accurately capture breathlessness during physical activity.

This study aims to evaluate whether the one-minute sit-to-stand test (1MSTS), a simple test that involves repeatedly standing up from and sitting down on a chair for one minute, can measure breathlessness during exercise. Adults with chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease (ILD) or heart failure (HF) will participate.

Participants will attend three study visits and complete exercise tests, including the 1MSTS, a six-minute walk test (6MWT), and cardiopulmonary exercise testing (CPET). The study will assess how well breathlessness measured during the 1MSTS test reflects breathlessness during other established exercise tests, and whether the test provides reliable and responsive measurements over time.

The results may help establish the 1MSTS as a practical and easy-to-use tool for assessing exertional breathlessness in both clinical practice and research.

Read the detailed description

Chronic breathlessness is a common and burdensome symptom among people with chronic respiratory and cardiovascular diseases. Accurate assessment of exertional breathlessness is important for clinical evaluation, monitoring of disease progression, and evaluation of treatment effects. Commonly used instruments, including symptom questionnaires, primarily rely on retrospective recall and may not adequately capture breathlessness experienced during physical activity.

The one-minute sit-to-stand test (1MSTS) is a simple, low-cost functional exercise test that can be performed in a wide range of healthcare settings. Although the test is increasingly used to assess functional capacity in patients with chronic disease, its role as a tool for assessing exertional breathlessness has not been fully established.

This prospective multicenter validation study aims to evaluate the measurement properties of breathlessness assessed during the 1MSTS in adults with chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease (ILD), and heart failure (HF). Participants will undergo repeated assessments using the 1MSTS and established exercise tests, including cardiopulmonary exercise testing (CPET) and the six-minute walk test (6MWT). Breathlessness will be assessed during exercise using standardised rating scales, and physiological responses will be recorded using conventional and sensor-based methods.

The study will examine the validity, reliability, and responsiveness of breathlessness measurements obtained during the 1MSTS. Findings from this study may support the use of the 1MSTS as a practical and accessible tool for identifying and monitoring exertional breathlessness in both clinical practice and research settings.

02

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)
  • Asthma (Diagnosis)
  • Interstitial Lung Disease (ILD)

Keywords

  • Breathlessness
  • Dyspnea
  • Exertional Breathlessness
  • One-Minute Sit-to Stand Test
  • COPD
  • Asthma
  • Interstitial Lung Disease
  • Heart Failure
  • Exercise testing
  • CPET
  • Six-Minute Walk Test
  • 6MWT
  • Functional Capacity
  • Validation Study
  • Sensor Technology
  • Wearable Sensors
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with chronic cardiorespiratory disease will be recruited from outpatient and primary care clinics. The study population will include individuals with COPD, asthma, ILD, or HF who are able to perform exercise testing and attend study visits.

Inclusion criteria

  • Have a physician diagnosis of COPD/ILD/Asthma/HF.
  • The participant has given written consent to participate in the study
  • Age 18 years or older
  • Able to cycle
  • Able to use the legs and stand up from sitting without risk of falling
  • Able to understand and speak Swedish to participate in the study procedures, as judged by the staff.

Exclusion criteria

Exclusion Criteria:

  • Resting peripheral oxygen saturation (SpO2) \< 92%
  • hospitalisation or clinical instability during the last four weeks
  • Treatment with supplementary oxygen at rest or during exercise
  • contraindication to exercise testing in accordance with clinical practice guidelines
  • expected survival shorter than six months as judged by the Staff
  • medical conditions including acute coronary artery disease, neuromuscular disease or severe psychiatric illness.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • COPD

    Individuals with COPD diagnosis

    Diagnostic Test: 1MSTS

  • Heart Failure

    Individuals with Heart Failure Diagnosis

    Diagnostic Test: 1MSTS

  • ILD

    Individuals with ILD diagnosis

    Diagnostic Test: 1MSTS

  • Asthma

    Individuals with Asthma diagnosis

    Diagnostic Test: 1MSTS

Interventions

  • Diagnostic test1MSTS

    The 1-minute Sit-to-Stand Test

05

What researchers measure

Primary outcomes

  1. Breathlessness intensity on BorgCR10 immediately after the 1MSTS

    Breathlessness intensity will be assessed immediately after completion of the 1MSTS using the Borg CR10 scale (range 0-10; higher scores indicate higher intensity of breathlessness). We will evaluate construct validity by comparing breathlessness intensity (Borg CR10) at peak exercise with CPET, the 6MWT, and self-reported breathlessness on the mMRC and disease-specific questionnaires.

    Time frame: Baseline (visit 1)

  2. Test-retest reliability of breathlessness intensity measured using BorgCR10 immediately after the 1MSTS

    Reproducibility of Borg CR10 breathlessness ratings (range 0-10; higher scores indicate higher intensity of breathlessness) obtained during repeated 1MSTS assessments.

    Time frame: Baseline (two 1MSTS assessments performed during Visit 1)

  3. Responsiveness of breathlessness intensity measured using the Borg CR10 immediately after the 1MSTS.

    Change in Borg CR10 breathlessness ratings (range 0-10; higher scores indicate higher intensity of breathlessness) immediately after 1MSTS between baseline and follow-up visits.

    Time frame: Baseline to final follow-up visit.

Secondary outcomes

  1. Diagnostic Accuracy of the 1MSTS for Identifying Abnormal Breathlessness

    Comparison of the ability of the 1MSTS, mMRC, and disease-specific questionnaires to identify abnormal exertional breathlessness using CPET and the 6MWT as reference measures. Sensitivity, specificity, and discrimination performance will be evaluated.

    Time frame: Baseline

  2. Threshold Values for Pathological Breathlessness

    Identification of clinically relevant 1MSTS breathlessness thresholds associated with abnormal exercise responses.

    Time frame: Baseline

  3. Wearable Sensor Performance Metrics

    Assessment of wearable sensor-derived measures of sit-to-stand performance and their association with breathlessness severity and exercise capacity.

    Time frame: Baseline

  4. Feasibility of the 1MSTS in Outpatient Care

    Assessment of test completion, safety, participant acceptability and practicality of the 1MSTS.

    Time frame: Baseline

  5. Prognostic Value of the 1MSTS

    Association between 1MSTS-derived breathlessness measures and subsequent clinical outcomes

    Time frame: Baseline up to 10 years

06

Study locations

1 site
  • Blekinge Institute of Technology
    Karlskrona, Blekinge County 37142, Sweden
07

References and documents

Study documents

  • Study protocol · Mar 30, 2026

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the reported results will be available upon reasonable request to the study investigators, subject to applicable ethical approvals, data protection regulations, and institutional requirements.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

08

Registry details

Key details

Study ID
NCT07836764
Lead sponsor
Jacob Sandberg
Collaborators
Lund University
Responsible party
Jacob Sandberg (Postdoctoral Researcher, Blekinge Institute of Technology) — Sponsor-investigator
First posted
Sep 23, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 23, 2026

Study contacts

Jacob Sandberg, M.D, PhD
Contact
jacob.sandberg@bth.se
+46734471519

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion